Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: Wright Reports
|
$472.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Stock Traders Daily
|
$495.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Onyx Pharmaceuticals Inc Submits New Drug Application For Regorafenib For Treatment Of Gastrointestinal Stromal Tumors
Onyx Pharmaceuticals Inc announced that Bayer HealthCare has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the oral multi-kinase inhibitor regorafenib for the treatment of metastatic and/or unresectable gastrointestinal stromal tumors (GIST) in patients whose disease has progressed despite prior treatment.
Latest Developments for Onyx Pharmaceuticals Inc
- Onyx Pharmaceuticals Inc's Stivarga (regorafenib) Tablets Approved By U.S. FDA For Treatment Of Patients With Locally Advanced, Unresectable Or Metastatic GIST
- Bayer AG's Bayer HealthCare Pharmaceuticals And Onyx Pharmaceuticals, Inc.'s Phase 3 DECISION Trial Of Nexavar (sorafenib) Meets Primary Endpoint
- Onyx Pharmaceuticals Inc Announces N. Anthony Coles, M.D. as Chairman of Board of Directors
- Onyx Pharmaceuticals, Inc., Bayer AG's HealthCare Pharmaceuticals And Astellas Pharma Inc Announce Tarceva To Nexavar Did Not Provide Additional Benefit To Patients
Latest Key Developments in Biotechnology
- Omeros Corp Announces Clearence Of New Drug Application By FDA For OMS824 In Huntington's Disease
- Miraca Holdings Inc Appoints Corporate Auditor
- Bioxyne Ltd Announces Termination Of Proposed Acquisition Of Vitality Devices Pty Ltd
- Repros Therapeutics Inc Announces That FDA Recommends Running Phase 2b Trial Of Proellex-V In Treatment of Severe Menstrual Bleeding Associated With Uterine Fibroids
- Share this
- Link this
- Digg this
Follow Reuters